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radiation therapy to the mediastinum (36 Gy). The
patient achieved CR in February 1995. Over the next
14 months she remained well and in complete hema-
tologic remission. In May 1996 she noted extensive
ecchymoses and petechiae. Her hematocrit was
43.2%, leukocyte count 0.643109/L and the platelet
count 1.03109/L. The spleen was not palpable and
there was no evidence of HD relapse. A bone marrow
biopsy revealed normal erythroid and myeloid matu-
ration. The diagnosis of ITP was suspected and a tri-
al of corticosteroids was begun. After 30 days the
platelet count was normal (2243109/L) and corti-
costeroids were stopped. To date, the patient
remains in complete hematologic (ITP) and HD
remission.  Although some studies have reported that
the presence of ITP in HD patients could signify active
lymphoma, especially with splenic involvement,2 oth-
er reports have shown that ITP can occur in the
absence of active HD,6 and that the HD status is
independent of the onset of ITP. 
Our two patients did not have active HD when they
developed ITP, and the development of ITP did not
indicate subsequent relapse, supporting the hypoth-
esis of two independent diseases with different
onsets. Furthermore, as for primary ITP occurring in
association with HD, so thrombocytopenic purpura
also seems to respond to conventional therapy.2 Both
patients responded with a single course of oral pred-
nisolone, but one relapsed after 15 months and
splenectomy was necessary for CR.5
The recognition of a picture of ITP as a complication
of HD could have important implications, as
described by Doan and Bouroncle.7 We suggest, there-
fore, that an occult HD should be considered in any
patient who presents with thrombocytopenic purpu-
ra of the ITP type, and particularly in a patient known
to have been previously treated for HD, where the ITP
picture may signal the recurrence of lymphoma. It
should be noted that we have also observed throm-
bocytopenic purpura in chronic myeloid leukemia
(CML) during treatment with interferon-a.8
In conclusion, ITP associated with HD responds to
therapy in a similar manner to that of primary ITP. Its
presence seems to confer no prognostic significance,9
although the possibility of localization of splenic HD
disease10 has to be considered.
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Human infections due to CDC group IV c-2, a gram-neg-
ative bacillus, are rare. We describe a case of nosoco-
mial bacteremia caused by this organism in a neu-
tropenic patient with acute lymphoblastic leukemia and
include a literature review of CDC group IV c-2 infection
in patients with hematologic malignancies.
Human infections due to CDC group IV c-2, a gram-
negative bacillus, have been recently reported.1-8 Bac-
teremia caused by this organism is rare in patients
with hematologic malignancies.2,5,6,8
We report here a case of septicemia caused by CDC
group IV c-2 in a neutropenic patient with acute
leukemia and review the literature on this entity
(MEDLINE, National Library of Medicine, Bethesda,
MD covering the years 1965-97).
A 71-year-old previously healthy woman was
admitted to our hospital with a temperature of
37.4ºC, dyspnea and pleuritic chest pain. The patient
had a history of fatigue, weakness and weight loss of
10 kg over the three previous months. Physical exam-
ination revealed cutaneous pallor, shortness of
breath and a few crackles at the left lung base. White
blood cell count was 1883109/L with 95% blastic
forms, the hemoglobin level was 6.8 g/dL and
platelet count 443109/L. A chest radiograph showed
a left lower lobe infiltrate and a small left pleural effu-
sion. Empirical therapy with amoxicillin/clavulanate
was administered intravenously. On the second day
of admission the patient was afebrile. Sputum and
blood cultures were negative.
Microscopical examination of a bone marrow aspi-
rate revealed acute lymphoblastic leukemia, L-2
according to the criteria of the FAB classification.
Immunophenotype was consistent with ALL-preB. An
induction chemotherapy regimen consisting of
daunorubicin, vincristine, L-asparaginase and pred-
nisone was initiated.
After two weeks of antibiotic treatment, the patien-
t’s condition improved and a new chest radiograph
was normal. Amoxicillin/clavulanate was stopped and
oral prophylaxis with norfloxacin was then initiated.
Twelve days later, while neutropenic, the patient’s
temperature rose to 38.5ºC and her blood pressure fell
to 80/50 mm Hg. After acquisition of two specimens
for blood culturing, fluid replacement was initiated
and, ceftazidime and amikacin were given intra-
venously. Twenty-four hours after beginning empiri-
cal antibiotic therapy she became afebrile with no clin-
ical signs of infection. A gram-negative rod was iso-
lated from all the blood cultures. Cultures from urine
and indwelling line specimens were negative.
The chemotherapy course was complicated by sev-
eral episodes of intestinal bleeding due to severe
thrombocytopenia. Several days later, the patient
became agitated and severe hypotension and oligoa-
nuria developed despite fluid replacement and
inotropic drug therapy. The patient died because of
a new bleeding episode. At that time blood cultures
were negative. 
The isolate was identified as CDC group IV c-2 by
conventional methods from the blood cultures after
72 hours. Its microbiological characteristics were con-
sistent with those previously defined for the bacil-
lus.9,10 With standard disk diffusion testing, the organ-
ism was susceptible to trimethoprim-sulfametho-
xazole, ciprofloxacin and ceftazidime, but was resis-
tant to ampicillin, amoxicillin plus clavulanate, piper-
acillin, ticarcillin, ticarcillin plus clavulanate, cephalo-
thin, cefoxitin, cefotaxime, ceftriaxone, imipenem,
aztreonam, gentamicin, tobramycin, amikacin and
tetracycline.
CDC group IV c-2 is a gram-negative environmen-
tal bacillus rarely isolated from clinical specimens.
However, several cases of well-documented infections
caused by this organism have been reported, with
eight cases of septicemia (five of them occurring in a
hospital outbreak),2,5,6,8 two cases of peritonitis relat-
ed to peritoneal catheter infection,1,4 one case of
plantar abscess complicated with bacteremia3 and
one case of tenosynovitis.7 All but one of these
patients had underlying disease. We found five pre-
viously reported cases of infection caused by CDC IV
c-2 in patients with hematologic malignancies in our
review of the literature.2,5,6,8 These 5 cases with the
addition of our case are summarized in Table 1. Four
patients had acute leukemia and two non-Hodgkin’s
lymphoma. Our review shows that most of the infec-
tions were nosocomial-acquired and presented with
bacteremia, mainly catheter-related, occurring during
chemotherapy-induced neutropenia.
In spite of the well-known severity of gram-negative
bacteremia in patients with cancer, all reported
patients with bacteremia caused by CDC group IV c-
2 were cured from infection following appropriate
antimicrobial therapy, probably indicating a low lev-
el of pathogenicity of this organism. It should be not-
ed that catheter removal was only necessary in one of
these cases.
It has been shown that CDC group IV c-2 is sus-
ceptible to a wide range of antimicrobial agents,
including aminopenicillins, antipseudomonal peni-
cillins, cephalosporins, carbapenems and fluoro-
quinolones. However, this organism is usually resis-
tant to aminoglycosides.1-8,10 In our case, the organ-
ism showed an unusual pattern of antibiotic-suscep-
tibility, showing resistance to a broad spectrum of
antimicrobial agents. To our knowledge, this is the
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Table 1. CDC group IV c-2 infection in patients with hematologic malignancies.
Reference Age/Sex Underlying condition Neutropenia Specimen cultured Source of infection Acquisition Outcome
Dan et al.2 37/M Plasma cell leukemia No Blood Unknown Community Recovery
Arduino et al.5 77/M Non Hodgkin’s lymphoma No? Blood Catheter Nosocomial Recovery
Ramos et al.6 10/F Acute leukemia Yes Blood Catheter Nosocomial Recovery
Moissenet et al.8 11/NR Non Hodgkin’s lymphoma* Yes Blood Catheter Nosocomial Recovery
Moissenet et al.8 14/NR Acute leukemia* Yes Blood Catheter Nosocomial Recovery
Salar et al.PR 77/F Acute leukemia Yes Blood Unknown Nosocomial Recovery
PR, present report; NR, not reported; *cases reported in a hospital outbreak of CDC group IV c-2 infection.
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first report in which resistance of this bacillus to
imipenem is noted.
In summary, CDC group IV c-2 bacillus is an
opportunistic pathogen that rarely causes bacteremia
in patients with hematologic malignancies and
indwelling intravenous lines.
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